mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients

Who May Qualify: - diagnosed by tissue sample (biopsy-confirmed) adenocarcinoma of the pancreas without distant metastases. - Receive radical resection of pancreatic cancer - No prior cytostatic chemotherapy - Female and male patients \> 18 and \<=79 years using contraception - ECOG ≤ 1 - Patient has adequate bone marrow and organ function - Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L platelet count at least 90 x 109/L blood count (hemoglobin) at least 90 g/L - Patient has adequate liver function AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis) Serum bilirubin ≤ 1.2 x ULN Creatinine ≤ 1.25 times ULN - Good compliance - Written willing to sign a consent form Who Should NOT Join This Trial: - Pregnant or lactating women - Distant metastasis. - Patients with severe gastrointestinal hemorrhage which need frequent blood transfusions. - Refuse to take appropriate contraceptive measures (including male patients). - Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil. - Severe systemic disease out of control such as unstable or uncompensated respiratory, cardiac, liver, renal diseases. - Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in situ). - Psychiatric illness that would prevent the patient from giving willing to sign a consent form. - Patient is concurrently using other antineoplastic agent - Patient has used investigational antineoplastic agent within 4 weeks prior to entry. - Known HIV-positivity. - No history of chronic diarrhea, nausea or vomit. - No ≥ grade 2 sensory peripheral neuropathy. - A history of transmural myocardial infarction (within 6 months prior to entry), congestive heart failure, and unstable angina. - Infectious disease or inflammation with body temperature ≥ 38 ℃. Always talk to your doctor about whether this trial is right for you.